These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 2938980

  • 1. Functional assay of plasminogen activator by hydrolysis of 14C-globin.
    Finci Z, Nachshon I, Sharoni Y, Mayer M.
    Exp Hematol; 1986 May; 14(4):293-7. PubMed ID: 2938980
    [Abstract] [Full Text] [Related]

  • 2. Assay method for single-chain urokinase-type plasminogen activator.
    Matsuo O, Ueshima S, Okada K, Fukao H, Ohgaki M, Watanabe R, Arimura H.
    Hematol Pathol; 1989 May; 3(3):137-42. PubMed ID: 2531734
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 6. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2.
    Liu JW, Wei DZ, Du CB, Zhong JJ.
    Acta Pharmacol Sin; 2003 Feb 20; 24(2):102-8. PubMed ID: 12546716
    [Abstract] [Full Text] [Related]

  • 7. A spectrophotometric assay for the determination of the catalytic efficiency of plasminogen activators using a slowly hydrolyzed plasmin substrate.
    Castro MJ, Kingston IB, Anderson S.
    Anal Biochem; 1995 Apr 10; 226(2):225-31. PubMed ID: 7793622
    [Abstract] [Full Text] [Related]

  • 8. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P, Kant KS, Allen C, Pollak VE.
    J Lab Clin Med; 1984 Dec 10; 104(6):962-76. PubMed ID: 6239000
    [Abstract] [Full Text] [Related]

  • 9. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M, Cavallo LG, Agnelli G, Mele A, Bürgi R, Heim J, Semeraro N.
    Thromb Haemost; 1993 May 03; 69(5):466-72. PubMed ID: 8391727
    [Abstract] [Full Text] [Related]

  • 10. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3).
    Ugwu F, Van Hoef B, Bini A, Collen D, Lijnen HR.
    Biochemistry; 1998 May 19; 37(20):7231-6. PubMed ID: 9585535
    [Abstract] [Full Text] [Related]

  • 11. Human hepatoma cell line plasminogen activator.
    Levin EG, Fair DS, Loskutoff DJ.
    J Lab Clin Med; 1983 Oct 19; 102(4):500-8. PubMed ID: 6311924
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM, Greco WR.
    Cancer Res; 1986 Apr 19; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [Abstract] [Full Text] [Related]

  • 13. Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).
    Ugwu F, Lemmens G, Collen D, Lijnen HR.
    Thromb Haemost; 1999 Sep 19; 82(3):1127-31. PubMed ID: 10494776
    [Abstract] [Full Text] [Related]

  • 14. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V, Pannell R, Broeze RJ, Mao J.
    J Clin Invest; 1988 Dec 19; 82(6):1956-62. PubMed ID: 2974047
    [Abstract] [Full Text] [Related]

  • 15. Tissue plasminogen activator binding to mouse cerebellar granule neurons.
    Verrall S, Seeds NW.
    J Neurosci Res; 1988 Dec 19; 21(2-4):420-5. PubMed ID: 3145983
    [Abstract] [Full Text] [Related]

  • 16. Plasminogen activator activity is decreased in rat gingiva during diabetes.
    Chang K, Rani AS, Chang K, Kumar S.
    J Periodontol; 1996 Aug 19; 67(8):743-47. PubMed ID: 8866312
    [Abstract] [Full Text] [Related]

  • 17. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
    Turner PC, Baquero MT, Yuan S, Thoennes SR, Moyer RW.
    Virology; 2000 Jul 05; 272(2):267-80. PubMed ID: 10873770
    [Abstract] [Full Text] [Related]

  • 18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S.
    Dan Med Bull; 1993 Sep 05; 40(4):383-408. PubMed ID: 8222763
    [Abstract] [Full Text] [Related]

  • 19. Fibrin-specific thrombolytic agents.
    Collen D.
    Schweiz Med Wochenschr; 1987 Nov 14; 117(46):1791-8. PubMed ID: 3122317
    [Abstract] [Full Text] [Related]

  • 20. Plasminogen activator activity in differentiating leukemia cells.
    Kidron M, Nachshon I, Mayer M, Fibach E.
    FEBS Lett; 1984 Nov 05; 177(1):66-70. PubMed ID: 6238843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.